NHS staff shortages mean patients miss out on early bowel cancer diagnosis

January 27, 2020

Around 1,100 people in England could miss out on the chance of an early stage bowel cancer diagnosis through screening each year because of NHS staff shortages, according to new calculations released by Cancer Research UK today.*

Bowel cancer screening tests look for hidden blood in the stool which can be an early sign of bowel cancer. But the new test, known as FIT, does not provide a simple yes or no answer.

It is up to the individual health systems to decide what level of haemoglobin - a protein found in blood - warrants further investigation, usually a colonoscopy. And this is where patients are missing out on potentially life-saving early diagnoses largely due to a lack of specialist staff.

NHS England and NHS Scotland have chosen different cut-off points for a referral following a screening test - 120 and 80 micrograms of haemoglobin per gram of faeces respectively. This means that in Scotland, the NHS refers people who have between 80 and 120 micrograms of haemoglobin, when the NHS in England does not.

And this equates to around 1,100 bowel cancers that could be diagnosed through the bowel cancer screening programme each year in England but are not.

The impact is even higher when we consider the number of pre-cancerous growths that could be detected and removed during a colonoscopy.

Cancer Research UK has calculated that if the NHS in England referred people with the same hidden blood levels as Scotland, there could be an additional 2,000 colonoscopies each month in England.** Although many of these would not turn out to be cancer, the NHS in England does not have enough endoscopists - people who look inside the body with a camera - nurses and other specialist staff to handle this.

Already one in 10 diagnostic posts are vacant in England. And the demand for staff is rising. Around 363,000 people are diagnosed with cancer each year in the UK but by 2035, that is likely to increase to around half a million people.***

When bowel cancer is diagnosed at the earliest stage, as it can be through screening, more than 9 in 10 people survive their disease for at least five years. But when it is detected in the late stages, survival falls to less than 1 in 10.****

Sara Hiom, Cancer Research UK's director of early diagnosis, said: "The UK's bowel cancer screening programme is very effective at detecting cancer early. But we're concerned that NHS staff shortages are having a direct impact on the ability to diagnose more patients at an early stage - something that the Government committed to doing last year. People shouldn't be slipping through the net.

"Improvements to cancer screening in the UK need to be made quickly and safely to ensure the NHS can diagnose people earlier. Even though NHS staff on the ground are doing everything they can to diagnose people early, the Government needs to back them up with significant investment to train and recruit more staff so that doctors, nurses and other specialists can diagnose more people at an early stage, when treatment is more likely to be successful."

FIT bowel screening is a more accurate way to test for early stage bowel cancer, than the previous test, known as gFOBT. It was introduced in England last year and has been running in Scotland for two years.

The latest figures show that around 42,000 people are diagnosed with bowel cancer each year in the UK which equates to more than 110 people every day. Around 16,300 people die from bowel cancer every year. And in England, more than half of bowel cancers with a known stage are diagnosed at a late stage.*****

Dr Ed Seward, consultant gastroenterologist and Cancer Research UK's clinical adviser said: "When we treat bowel cancer patients who were diagnosed at an early stage, we have curative treatments we can offer, including surgery. It can be devastating to patients and their families when the disease is caught at a late stage, which is why the bowel screening programme is so important - finding cancers when they haven't caused symptoms at all. So we really don't want to see patients missing out on a potentially life-saving opportunity."

Notes to editor:

FIT stands for Faecal Immunochemical Test. It is a type of faecal occult blood test which uses antibodies that specifically recognise human haemoglobin (Hb). It is used to detect, and can quantify, the amount of human blood in a single stool sample. An abnormal result suggests that there may be bleeding within the gastrointestinal tract that requires further investigation. Those with an abnormal result are then invited for further testing via a colonoscopy. NHS England has committed to optimising bowel screening, which includes extending the age and reducing the threshold. This will require more staff. The bowel screening programme is intended for people without any signs or symptoms suggestive of bowel cancer.

There have been some positive steps in the short term to tackle staff shortages. For example, Health Education England has funded a clinical endoscopist programme, which trains nurses and other healthcare professionals to deliver some of the tests that can diagnose bowel cancer. HEE has also recently announced funding for advanced training for scientists working in healthcare to handle and report biopsy samples. The Government has announced a 3.4% real terms spending increase for the HEE budget in 2020/21. This is a positive first step but would only equate to about £220m additional investment. Growing the workforce in the long-term requires sustained investment in the Spending Review which is expected later this year.

NHS England's forthcoming People Plan is a vital opportunity for the NHS to set out plans for increasing the cancer workforce. However, in order to make this happen, the Government would have to invest specifically in the NHS workforce.
*Estimates are based on the rate of participation and the cancer detection rate for the relevant threshold from the England FIT pilot in 2014 (data based on Moss et al., Gut; 2016), and assume 4.6 million screening programme invites for 60-74 years olds in England per year. Estimates are for the years immediately following the introduction of FIT.

**Estimates are based on the rate of participation and positivity rate for the relevant threshold from the England FIT pilot in 2014 (data based on Moss et al., Gut; 2016), and assume 85% uptake of colonoscopy. Estimates do not include surveillance colonoscopies and are for the years immediately following the introduction of FIT.

***Based on incidence projection for the UK up to 2035 from Smittenaar et al. 2016

****Source: ONS Cancer Survival in England - adults diagnosed, accessed 01/11/19 https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/cancersurvivalratescancersurvivalinenglandadultsdiagnosed

*****Annual average number of new cases of cancer (ICD10 C00-C97) diagnosed in the UK between 2014 and 2016.

Annual average number of deaths from cancer (ICD10 C00-C97) in the UK between 2015 and 2017

56% of known stage bowel cancers in England are diagnosed late (stage 3 or 4). National Cancer Registration and Analysis Service (NCRAS)

About Cancer Research UKFor further information about Cancer Research UK's work or to find out how to support the charity, please call 0300 123 1022 or visit http://www.cancerresearchuk.org. Follow us on Twitter and Facebook.

Cancer Research UK

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.